Cargando…

A dual functional ruthenium arene complex induces differentiation and apoptosis of acute promyelocytic leukemia cells

Human acute promyelocytic leukemia (APL) is the most malignant form of acute leukemia. The fusion of PML and RARα genes is responsible for over 98% of cases of APL. In this work, we found that a Ru(ii) arene complex, [(η(6)-p-bip)Ru(en)Cl][PF(6)] (Ru-1), can selectively react with PML, leading to zi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hai, Cao, Kaiming, Kong, Yaqiong, Yuan, Siming, Liu, Hongke, Wang, Yucai, Liu, Yangzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993625/
https://www.ncbi.nlm.nih.gov/pubmed/32055340
http://dx.doi.org/10.1039/c9sc03110c
Descripción
Sumario:Human acute promyelocytic leukemia (APL) is the most malignant form of acute leukemia. The fusion of PML and RARα genes is responsible for over 98% of cases of APL. In this work, we found that a Ru(ii) arene complex, [(η(6)-p-bip)Ru(en)Cl][PF(6)] (Ru-1), can selectively react with PML, leading to zinc-release and protein unfolding. Consequently, the degradation of the fusion protein PML–RARα occurs, which causes the differentiation of APL cells. In addition, Ru-1 can also bind to DNA and trigger apoptosis of APL cells. Therefore, Ru-1 acts as a dual functional agent that inhibits the growth of APL cells and induces cell differentiation. In contrast, the other non-selective Ru(ii) compound, though also highly reactive to PML, does not exhibit anti-APL activity. The selectivity of Ru-1 to PML suggests a new strategy for the development of anti-APL drugs using ruthenium agents.